What goes around comes around: novel pharmacological targets in the gut-brain axis
Author
dc.contributor.author
Gonzalez Arancibia, Camila
Author
dc.contributor.author
Escobar Luna, Jorge
Author
dc.contributor.author
Barrera Bugueno, Camila
Author
dc.contributor.author
Díaz Zepeda, Camilo
Author
dc.contributor.author
González Toro, Maria P.
Author
dc.contributor.author
Olavarría Ramirez, Loreto
Author
dc.contributor.author
Zanelli Massai, Francesca
Author
dc.contributor.author
Gotteland, Martin
Author
dc.contributor.author
Bravo, Javier A.
Author
dc.contributor.author
Julio Pieper, Marcela
Admission date
dc.date.accessioned
2016-09-28T14:51:59Z
Available date
dc.date.available
2016-09-28T14:51:59Z
Publication date
dc.date.issued
2016-05
Cita de ítem
dc.identifier.citation
Ther Adv Gastroenterol 2016, Vol. 9(3) 339– 353
es_ES
Identifier
dc.identifier.issn
1756-2848
Identifier
dc.identifier.other
10.1177/1756283X16630718
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/140534
Abstract
dc.description.abstract
The gut and the brain communicate bidirectionally through anatomic and humoral pathways, establishing what is known as the gut-brain axis. Therefore, interventions affecting one system will impact on the other, giving the opportunity to investigate and develop future therapeutic strategies that target both systems. Alterations in the gut-brain axis may arise as a consequence of changes in microbiota composition (dysbiosis), modifications in intestinal barrier function, impairment of enteric nervous system, unbalanced local immune response and exaggerated responses to stress, to mention a few. In this review we analyze and discuss several novel pharmacological targets within the gut-brain axis, with potential applications to improve intestinal and mental health.